Karyopharm Therapeutics
KPTI
KPTI
47 hedge funds and large institutions have $13.7M invested in Karyopharm Therapeutics in 2025 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 8 increasing their positions, 30 reducing their positions, and 42 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
73% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 30
95% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 42
Holders
47
Holding in Top 10
–
Calls
$581K
Puts
$95K
Top Buyers
| 1 | +$570K | |
| 2 | +$523K | |
| 3 | +$457K | |
| 4 |
EP
Eversept Partners
New York
|
+$441K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$314K |
Top Sellers
| 1 | -$1.08M | |
| 2 | -$863K | |
| 3 | -$837K | |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
-$808K |
| 5 |
SCM
Silverarc Capital Management
Boston,
Massachusetts
|
-$403K |
